Literature DB >> 22635229

The relationship between TORCH complex false positivity and obstetric outcome in patients with antiphospholipid syndrome.

S De Carolis1, S Santucci, A Botta, S Salvi, V A Degennaro, C Garufi, S Garofalo, S Ferrazzani, G Scambia.   

Abstract

OBJECTIVE: The presence of TORCH IgM positivity is not a specific indicator of primary infection; the assessment of IgG avidity index has been shown to be useful in identifying or excluding primary infection in pregnant women with no pre-gestational TORCH serology. TORCH is an acronym for Toxoplasmosis, Others (HBV, syphilis, Varicella-Zoster virus, Epstein Barr virus, Coxsackie virus and Parvovirus), Rubella, Cytomegalovirus (CMV) and Herpes Simplex. PATIENTS AND METHODS: Data from 54 pregnancies in women with antiphospholipid syndrome (APS) were assessed in comparison with data from 222 healthy pregnant women as controls. Each woman in both groups was systematically screened for TORCH IgG and IgM during pre-conceptional evaluation and/or at the beginning of pregnancy. The assessment of IgG avidity was also evaluated in order to identify primary infection or false positivity.
RESULTS: A significant increase of CMV IgM false positivity in APS in comparison with controls was detected. A worse pregnancy outcome was observed among APS patients having CMV IgM false positivity in comparison with APS patients without false positivity; in particular a statistically significant lower neonatal birth weight and a lower neonatal birth weight percentile were observed.
CONCLUSION: Our data suggest that the presence of CMV IgM false positivity could represent a novel prognostic factor for poor pregnancy outcome in APS patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22635229     DOI: 10.1177/0961203312447866

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  6 in total

1.  What is the best time to assess the antiphospholipid antibodies (aPL) profile to better predict the obstetric outcome in antiphospholipid syndrome (APS) patients?

Authors:  Jose Omar Latino; Sebastián Udry; Silvia Perés Wingeyer; Diego Fernández Romero; Paula Micone; Gabriela de Larrañaga
Journal:  Immunol Res       Date:  2018-10       Impact factor: 2.829

2.  Evaluation of different confirmatory algorithms using seven treponemal tests on Architect Syphilis TP-positive/RPR-negative sera.

Authors:  S Jonckheere; M Berth; M Van Esbroeck; S Blomme; K Lagrou; E Padalko
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-07-18       Impact factor: 3.267

3.  Evaluation of the BioPlex 2200 syphilis system as a first-line method of reverse-sequence screening for syphilis diagnosis.

Authors:  Antonella Marangoni; Paola Nardini; Claudio Foschi; Alessandra Moroni; Antonietta D'Antuono; Letizia Bacchi Reggiani; Roberto Cevenini
Journal:  Clin Vaccine Immunol       Date:  2013-05-22

Review 4.  Performance of Zika Assays in the Context of Toxoplasma gondii, Parvovirus B19, Rubella Virus, and Cytomegalovirus (TORCH) Diagnostic Assays.

Authors:  Bettie Voordouw; Barry Rockx; Thomas Jaenisch; Pieter Fraaij; Philippe Mayaud; Ann Vossen; Marion Koopmans
Journal:  Clin Microbiol Rev       Date:  2019-12-11       Impact factor: 26.132

5.  Prematurity and Low Birth Weight did not Correlate with Anti-Toxoplasma gondii Maternal Serum Profiles--a Brazilian Report.

Authors:  Mariana Machado Lemos Fochi; Sabrina Baring; Lígia Cosentino Junqueira Franco Spegiorin; Denise Cristina Mós Vaz-Oliani; Eloisa Aparecida Galão; Antonio Hélio Oliani; Luiz Carlos de Mattos; Cinara Cássia Brandão de Mattos
Journal:  PLoS One       Date:  2015-07-20       Impact factor: 3.240

6.  Seasonal influence on TORCH infection and analysis of multi-positive samples with indirect immunofluorescence assay.

Authors:  Lu Chen; Jingrui Liu; Lei Shi; Yang Song; Yujie Song; Yang Gao; Ying Dong; Lin Li; Min Shen; Yanhong Zhai; Zheng Cao
Journal:  J Clin Lab Anal       Date:  2019-01-21       Impact factor: 2.352

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.